April 15, 2024
Soleno Therapeutics Publicizes Financing Dedication for up

Funding from three main healthcare traders, with Vivo Capital becoming a member of current traders Nantahala Capital and Abingworth

$10 million capital infusion at closing and $15 million upon constructive information to help NDA submission

Extra $35 million capital upon FDA approval to allow commercialization

REDWOOD CITY, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical firm growing novel therapeutics for the therapy of uncommon ailments, right now introduced it has entered right into a Securities Buy Settlement with Nantahala Capital Administration, LLC, Abingworth LLP and Vivo Capital, LLC for as much as $60 million.

“This dedication from top-tier traders is a big demonstration of confidence forward of anticipated information from the randomized withdrawal interval of Examine C602 in mid-2023. It strengthens our stability sheet each close to and long term and helps continued preparation for our deliberate New Drug Software submission, in addition to the acceleration of economic readiness actions,” stated Anish Bhatnagar, M.D., Chief Govt Officer of Soleno Therapeutics. “As well as, we’re happy to report that the speed of enrollment within the research at our U.S. websites is progressing in step with our expectations. We anticipate initiating our U.Okay. websites shortly, which will depend on the timing of native regulatory and ethics processes.”

Beneath the phrases of the settlement, the traders have dedicated to pay $10 million in trade for warrants to buy frequent inventory upon the Firm’s announcement of enrollment completion within the randomized withdrawal interval of Examine C602, anticipated in Q1 2023. The warrants encompass two tranches. Tranche A warrants to buy as much as 8,598,870 shares of frequent inventory at $1.75 for a complete of roughly $15 million are required to be exercised inside 30 days of announcement of constructive top-line information from the randomized withdrawal interval of Examine C602. Tranche B warrants to buy as much as 14,000,000 shares of frequent inventory at $2.50 for a complete of $35 million expire upon the sooner of three.5 years from the date of issuance and 30 days following receipt of U.S. Meals and Drug Administration approval of DCCR for the therapy of PWS. The full doable proceeds raised underneath this settlement is $60 million for the issuance of twenty-two.6 million shares at a median worth of $2.65 per share, which represents a considerable premium over the December 16, 2022, closing worth of $0.91.

The randomized withdrawal interval of Examine C602 is a multi-center, randomized, double-blind, placebo-controlled research of DCCR in roughly 80 sufferers with PWS at 17 websites within the U.S. and 5 websites within the U.Okay. The randomized withdrawal interval consists solely of sufferers presently enrolled in Examine C602. Sufferers are randomized to obtain both DCCR or placebo for a interval of 4 months.

About PWS
The Prader-Willi Syndrome Affiliation USA estimates that PWS happens in a single in each 15,000 stay births within the U.S. The hallmark symptom of this dysfunction is hyperphagia, a continual feeling of insatiable starvation that severely diminishes the standard of life for PWS sufferers and their households. Extra traits of PWS embody behavioral issues, cognitive disabilities, low muscle tone, quick stature (when not handled with progress hormone), the buildup of extra physique fats, developmental delays, and incomplete sexual improvement. Hyperphagia can result in important morbidities (e.g., weight problems, diabetes, heart problems) and mortality (e.g., abdomen rupture, choking, unintentional dying on account of meals in search of habits). In a world survey carried out by the Basis for Prader-Willi Analysis, 96.5% of respondents (guardian and caregivers) rated hyperphagia and 92.9 % physique composition as crucial or a vital symptom to be relieved by a brand new medication. There are presently no permitted therapies to deal with the hyperphagia/urge for food, metabolic, cognitive perform, or behavioral features of the dysfunction. Diazoxide choline has acquired Orphan Drug Designation for the therapy of PWS within the U.S. and E.U., and Quick Observe Designation within the U.S.

About DCCR (Diazoxide Choline) Prolonged-Launch Tablets
DCCR is a novel, proprietary extended-release dosage kind containing the crystalline salt of diazoxide and is run once-daily. The guardian molecule, diazoxide, has been used for many years in 1000’s of sufferers in a couple of uncommon ailments in neonates, infants, kids and adults, however has not been permitted to be used in PWS. Soleno conceived of and established intensive patent safety on the therapeutic use of diazoxide and DCCR in sufferers with PWS. The DCCR improvement program is supported by information from 5 accomplished Part 1 scientific research in wholesome volunteers and three accomplished Part 2 scientific research, certainly one of which was in PWS sufferers. Within the PWS Part 3 research, DCCR confirmed promise in addressing hyperphagia, the hallmark symptom of PWS, in addition to a number of different signs resembling aggressive/harmful behaviors, fats mass and different metabolic parameters.

About Soleno Therapeutics, Inc.
Soleno is concentrated on the event and commercialization of novel therapeutics for the therapy of uncommon ailments. The corporate’s lead candidate, DCCR extended-release tablets, a once-daily oral pill for the therapy of Prader-Willi syndrome (PWS), is presently being evaluated in a Part 3 scientific improvement program. For extra info, please go to www.soleno.life.

Ahead-Wanting Statements
This press launch incorporates forward-looking statements inside the that means of Part 21E of the Securities Change Act of 1934, as amended. All statements aside from statements of historic information contained on this press launch are forward-looking statements, together with statements concerning timing closing of the providing, timing of any regulatory course of or final approvals and figuring out a path ahead for DCCR for the therapy of PWS. In some circumstances, you’ll be able to establish forward-looking statements by phrases resembling “could,” “will,” “ought to,” “anticipate,” “plan,” “anticipate,” “may,” “intend,” “goal,” “venture,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “proceed” or the unfavourable of those phrases or different comparable expressions. These forward-looking statements communicate solely as of the date of this press launch and are topic to various dangers, uncertainties and assumptions, together with the dangers and uncertainties related to market situations, in addition to dangers and uncertainties inherent in Soleno’s enterprise, together with these described within the firm’s prior press releases and within the periodic stories it recordsdata with the SEC. The occasions and circumstances mirrored within the firm’s forward-looking statements might not be achieved or happen and precise outcomes may differ materially from these projected within the forward-looking statements. Besides as required by relevant legislation, the corporate doesn’t plan to publicly replace or revise any forward-looking statements contained herein, whether or not because of any new info, future occasions, modified circumstances or in any other case.

Company Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

Soleno Therapeutics Publicizes Financing Dedication for up